This medical specialty focuses on the diagnosis and treatment of unusual bacterial, viral and communicable diseases, including hepatitis, meningitis, tuberculosis, Lyme Disease, etc. Children with recurring or persistent disease or infection caused by bacteria, a fungus, a parasite or an unknown cause are treated by pediatric infectious diseases specialists from birth through adolescence.
HFCH was the first facility in West Virginia to provide a dedicated pediatric space for COVID-19 monoclonal antibody infusions. Monoclonal antibody infusions may be given to patients 12 and older who test positive for COVID-19, show mild symptoms and are considered high-risk for severe illness due to additional health factors, such as diabetes or chronic respiratory disease. Antibodies must be administered within seven days of the onset of symptoms.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. After entering the body, the monoclonal antibodies attach to the spike protein on the outer surface of the coronavirus that causes COVID-19. When the antibodies attach, they can block the virus’ ability to enter cells and slow down the infection. In 2020, the Food and Drug Administration (FDA) provided emergency use authorization (EUA) for several different monoclonal antibodies to treat COVID-19.
Parents/guardians with a child who tests positive for COVID-19 should contact their child’s pediatrician to determine eligibility for an infusion. Referrals to the Hoops Outpatient Infusion Center may be made by both MHN and non-MHN providers. Physicians who have questions or would like to schedule an infusion, please call 304.399.1812.